Aarti Drugs quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	703	591	+19.0%
EBITDA	98.2	74.1	+32.6%
EBITDA margin	14.0%	12.6%	+1.4 pts
Profit before tax	69.2	51.1	+35.5%
Net profit	50.1	54.0	−7.1%
EPS	₹5.49	₹5.91	−7.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	703	720	602	653	591	677	557	598	555	620	606	642	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.8	0.8	1.2	0.1	0.3	1.9	11.9	1.5	1.1	1.1	1.7	0.7
	704	721	603	653	591	679	569	600	556	621	608	642
	469	427	335	385	357	375	370	346	348	367	401	396
	21.4	33.3	22.5	30.6	28.6	23.1	14.1	29.6	17.5	20.3	−21.7	42.2
	−63.1	−10.1	29.6	−7.4	−12.5	38.6	−32.5	18.9	−5.5	10.1	25.9	−8.8
	36.5	32.3	33.2	33.1	30.8	31.4	27.8	26.6	26.4	25.9	25.6	25.5
	9.2	8.2	9.3	7.7	8.6	9.2	9.1	8.9	8.7	9.1	7.6	8.3
	18.5	18.0	18.0	16.3	14.7	14.9	13.8	13.7	13.4	13.6	12.7	12.6
	140	142	127	127	112	115	116	111	104	111	105	111
	632	651	574	592	540	607	518	554	512	557	556	586
	98.2	95.8	55.0	84.3	74.1	93.3	61.7	67.1	65.0	85.8	70.1	76.5
	79.7	77.8	37.1	68.0	59.4	78.4	47.9	53.3	51.6	72.2	57.5	63.8
Profit
	71.3	70.4	29.0	60.4	51.1	71.2	50.8	45.9	44.0	64.2	51.6	56.3
	−2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	69.2	70.4	29.0	60.4	51.1	71.2	50.8	45.9	44.0	64.2	51.6	56.3
	18.1	17.7	−13.5	13.6	−4.5	10.4	12.0	8.8	10.0	15.1	14.3	15.4
	1.1	−2.6	2.0	1.6	1.7	−2.0	1.7	2.1	0.7	1.8	0.6	1.3
	19.1	15.1	−11.5	15.3	−2.9	8.4	13.7	10.9	10.7	16.9	14.8	16.7
	50.1	55.3	40.6	45.2	54.0	62.8	37.1	35.0	33.3	47.3	36.7	39.6
	50.1	55.3	40.6	45.2	54.0	62.8	37.1	35.0	33.3	47.3	36.7	39.6
	0.1	2.8	0.3	0.0	0.1	1.3	−0.5	0.4	0.4	0.1	0.0	0.0
	50.2	58.0	40.9	45.2	54.1	64.1	36.6	35.3	33.7	47.4	36.7	39.6
	50.2	55.2	40.5	45.3	53.9	62.9	37.1	35.0	33.2	47.4	36.7	39.6
	−0.0	0.1	0.0	−0.1	0.1	−0.1	0.0	−0.0	0.0	−0.1	0.0	0.0
Per share
	₹5.49	₹6.05	₹4.44	₹4.95	₹5.91	₹6.88	₹4.06	₹3.83	₹3.62	₹5.15	₹3.99	₹4.29
	₹5.49	₹6.05	₹4.44	₹4.95	₹5.91	₹6.88	₹4.06	₹3.83	₹3.62	₹5.15	₹3.99	₹4.29
Other comprehensive income — detail
	0.1	2.8	0.3	0.0	0.1	1.3	—	—	—	—	—	—
	0.1	2.8	0.3	0.0	0.1	1.3	—	0.4	0.4	0.1	—	—
	50.2	58.0	40.8	45.3	54.0	64.1	36.6	35.3	33.6	47.4	36.7	39.6
	−0.0	0.1	0.0	−0.1	0.1	−0.1	0.0	−0.0	0.0	−0.1	0.0	0.0
Per share — as-filed variants
	₹5.49	₹6.05	₹4.44	₹4.95	₹5.91	₹6.88	₹4.06	₹3.83	₹3.62	₹5.15	₹3.99	₹4.29
	₹5.49	₹6.05	₹4.44	₹4.95	₹5.91	₹6.88	₹4.06	₹3.83	₹3.62	₹5.15	₹3.99	₹4.29
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	275	270	215	245	217	240	205	204	196	223	201	213
	39.2%	37.5%	35.7%	37.5%	36.8%	35.4%	36.9%	34.2%	35.2%	36.0%	33.1%	33.1%
Adjusted (ex-exceptional items) — derived
	71.3	70.4	29.0	60.4	51.1	71.2	50.8	45.9	44.0	64.2	51.6	56.3
	−2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	51.6	55.3	40.6	45.2	54.0	62.8	37.1	35.0	33.3	47.3	36.7	39.6
	₹5.66	₹6.05	₹4.44	₹4.95	₹5.91	₹6.88	₹4.06	₹3.83	₹3.62	₹5.15	₹3.99	₹4.29

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersALIVUS AARTIPHARM ADVENZYMES AGARWALEYE AKUMS APLLTD CORONA HCGMcap ₹4,098 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	641.5	605.9	620.0	555.3	598.3	556.6	676.8	590.5	652.8	601.7	720.3	702.8
Other Income	0.7	1.7	1.1	1.1	1.5	11.9	1.9	0.3	0.1	1.2	0.8	0.8
Total Income	642.2	607.6	621.1	556.5	599.8	568.5	678.6	590.8	652.9	602.9	721.1	703.6
Expenses
+ Cost of Materials Consumed	395.7	401.1	366.6	347.8	345.6	369.8	375.1	357.3	385.1	334.5	427.2	469.4
+ Purchases of Stock-in-Trade	42.2	-21.7	20.3	17.5	29.6	14.1	23.1	28.6	30.6	22.5	33.3	21.4
+ Changes in Inventories	-8.8	25.9	10.1	-5.5	18.9	-32.5	38.6	-12.5	-7.4	29.6	-10.1	-63.1
+ Employee Benefit Expense	25.5	25.6	25.9	26.4	26.6	27.8	31.4	30.8	33.1	33.2	32.3	36.5
+ Finance Costs	8.3	7.6	9.1	8.7	8.9	9.1	9.2	8.6	7.7	9.3	8.2	9.2
+ Depreciation & Amortisation	12.6	12.7	13.6	13.4	13.7	13.8	14.9	14.7	16.3	18.0	18.0	18.5
+ Other Expenses	110.6	105.0	111.2	104.1	110.7	115.7	115.2	112.2	127.2	126.9	141.8	140.5
Total Expenses	586.0	556.1	556.9	512.5	553.9	517.7	607.5	539.7	592.5	573.9	650.7	632.3
EBITDA	76.5	70.1	85.8	65.0	67.1	61.7	93.3	74.1	84.3	55.0	95.8	98.2
EBIT	63.8	57.5	72.2	51.6	53.3	47.9	78.4	59.4	68.0	37.1	77.8	79.7
Profit
PBT before Exceptional Items	56.3	51.6	64.2	44.0	45.9	50.8	71.2	51.1	60.4	29.0	70.4	71.3
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1
Pretax Income	56.3	51.6	64.2	44.0	45.9	50.8	71.2	51.1	60.4	29.0	70.4	69.2
+ Current Tax	15.4	14.3	15.1	10.0	8.8	12.0	10.4	-4.5	13.6	-13.5	17.7	18.1
+ Deferred Tax	1.3	0.6	1.8	0.7	2.1	1.7	-2.0	1.7	1.6	2.0	-2.6	1.1
Tax Expense	16.7	14.8	16.9	10.7	10.9	13.7	8.4	-2.9	15.3	-11.5	15.1	19.1
Net Income	39.6	36.7	47.3	33.3	35.0	37.1	62.8	54.0	45.2	40.6	55.3	50.1
+ Net Income — Continuing Ops	39.6	36.7	47.3	33.3	35.0	37.1	62.8	54.0	45.2	40.6	55.3	50.1
+ Other Comprehensive Income	0.0	0.0	0.1	0.4	0.4	-0.5	1.3	0.1	0.0	0.3	2.8	0.1
Total Comprehensive Income	39.6	36.7	47.4	33.7	35.3	36.6	64.1	54.1	45.2	40.9	58.0	50.2
Net Income to Common	39.6	36.7	47.4	33.2	35.0	37.1	62.9	53.9	45.3	40.5	55.2	50.2
Minority Interest	0.0	0.0	-0.1	0.0	-0.0	0.0	-0.1	0.1	-0.1	0.0	0.1	-0.0
Per Share
Basic EPS	4.29	3.99	5.15	3.62	3.83	4.06	6.88	5.91	4.95	4.44	6.05	5.49
Diluted EPS	4.29	3.99	5.15	3.62	3.83	4.06	6.88	5.91	4.95	4.44	6.05	5.49
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	1.3	0.1	0.0	0.3	2.8	0.1
+ Items NOT to be Reclassified to P&L	—	—	0.1	0.4	0.4	—	1.3	0.1	0.0	0.3	2.8	0.1
Comprehensive Income — Owners of Parent	39.6	36.7	47.4	33.6	35.3	36.6	64.1	54.0	45.3	40.8	58.0	50.2
Comprehensive Income — Non-controlling Interests	0.0	0.0	-0.1	0.0	-0.0	0.0	-0.1	0.1	-0.1	0.0	0.1	-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	4.29	3.99	5.15	3.62	3.83	4.06	6.88	5.91	4.95	4.44	6.05	5.49
Diluted EPS — Continuing Operations	4.29	3.99	5.15	3.62	3.83	4.06	6.88	5.91	4.95	4.44	6.05	5.49
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	212.5	200.7	222.9	195.5	204.3	205.2	239.9	217.1	244.5	215.1	269.9	275.2
Gross Margin %	33.12	33.12	35.95	35.21	34.15	36.87	35.44	36.77	37.45	35.74	37.47	39.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	56.3	51.6	64.2	44.0	45.9	50.8	71.2	51.1	60.4	29.0	70.4	71.3
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1
Net Income Adj (tax-effected)	39.6	36.7	47.3	33.3	35.0	37.1	62.8	54.0	45.2	40.6	55.3	51.6
EPS Adj	4.29	3.99	5.15	3.62	3.83	4.06	6.88	5.91	4.95	4.44	6.05	5.66
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	91.9	91.9	91.9	91.9	91.3	91.3	91.3	91.3	91.3	91.3	91.3	91.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Aarti Drugs Q2 FY27 results date

Aarti Drugs (NSE: AARTIDRUGS) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 27 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹50.2 crore, down 6.9% from ₹53.9 crore in Q1 FY26 and down 9.1% from ₹55.2 crore in Q4 FY26. Revenue from operations was ₹703 crore, up 19.0% year on year and down 2.4% from the previous quarter.

Board-meeting notice filed: 27 October 2026
Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 31 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 27 Oct
Q1 FY27 net profit: ₹50.2 Cr−6.9% vs Q1 FY26−9.1% vs Q4 FY26
Q1 FY27 revenue: ₹703 Cr+19.0% vs Q1 FY26−2.4% vs Q4 FY26
Q1 FY27 operating margin: 11.3%+1.3 pts vs Q1 FY26+0.6 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹45.3 CrRevenue ₹653 Cr
Q1 FY27 EPS (basic): ₹5.49

Questions

When will Aarti Drugs announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 27 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What were Aarti Drugs' Q1 FY27 results?

Consolidated net profit was ₹50.2 crore, down 6.9% from ₹53.9 crore in Q1 FY26 and down 9.1% from ₹55.2 crore in Q4 FY26. Revenue from operations was ₹703 crore, up 19.0% year on year and down 2.4% from the previous quarter.

What was Aarti Drugs' revenue in FY26?

Revenue from operations was ₹2,565 crore in FY26 (April 2025–March 2026), up 7.5% from ₹2,387 crore in FY25. It was ₹2,529 crore in FY24 and ₹2,716 crore in FY23: down 5.5% over three years, an average fall of 1.9% a year.

What will Aarti Drugs' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹45.3 crore and revenue from operations ₹653 crore. The latest quarter, Q1 FY27, had a net profit of ₹50.2 crore and revenue of ₹703 crore.

How has Aarti Drugs' profit changed over the last four quarters?

Net profit by quarter: ₹45.3 crore in Q2 FY26, ₹40.5 crore in Q3 FY26, ₹55.2 crore in Q4 FY26 and ₹50.2 crore in Q1 FY27. That is ₹191 crore over the four quarters, up 1.2% from ₹189 crore in the four quarters before. Revenue from operations: ₹653 crore, ₹602 crore, ₹720 crore and ₹703 crore.

What was Aarti Drugs' net profit in FY26?

Consolidated net profit was ₹195 crore in FY26 (April 2025–March 2026), up 15.9% from ₹168 crore in FY25. It was ₹171 crore in FY24 and ₹166 crore in FY23: up 17.2% over three years, 5.4% a year on average.

Where do these Aarti Drugs figures come from?

From Aarti Drugs' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.